Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in three upcoming conferences in September during which he will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday, September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m. Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas Weisel Partners Healthcare Conference and Citi Biotech Day will be available for 10 business days following each conference. Each webcast can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors,
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... that American Indians largely were wiped out by diseases ... brought to the New World by European explorers., One ... lived in the Americas shortly before Europeans arrived, and ... diseases., But new research led by anthropological geneticists Anne ... the University of Tubingen in Germany indicates the diagnosis ...
(Date:8/20/2014)... Group finds that the vascular access device market in ... and China (BRIC) was valued ... of the United States market that year. ... as a result of strong economic expansion, improving access to healthcare ... Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... JOSE, Calif. , Aug. 20, 2014 /PRNewswire-iReach/ ... highlights the transformative collaboration between the school,s bioengineering ... As part of the Intel® Software Academic Program, ... computer sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
... , SAN DIEGO, Dec. 11 Ambit ... Texas M. D. Anderson Cancer Center of the first patient in the ... Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid ... selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 ...
... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... of Dr. Alan Warrander to the role of Senior ... Warrander will be responsible for the execution of the ... President and CEO of Oncolytics. "Having reached an agreement ...
Cached Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... NOAA/Virginia Sea Grant has awarded Virginia Tech $119,000 to ... virus in both shucked and unshucked oysters. , The ... High Pressure Processing Laboratory, and Laura Douglas, lab manager, ... schedules. The laboratory is a facility of the Department ...
... a new protein that plays a critical role in enabling ... or stress, as well as in the progressive loss of ... Their findings, they said, suggest new approaches to prevent or ... in the U.S. The team reports its findings in the ...
... lifespan in yeast, worms, and flies keeps blood sugar ... the August Cell Metabolism. The findings suggest therapeutic interventions ... as type 2 diabetes, which frequently arise with age, ... with an excess of the protein Sirt1 in cells ...
Cached Biology News:Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied 2Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy 2Life-extending protein keeps blood sugar in check 2
... Protein Purification Plates are designed for quick ... The 96-well plates feature two 0.25mm holes ... each well. The wells remain liquid-tight during ... during which time the protein diffuses from ...
... the state-of-the-art in permanent mounting media. ... preservation of immunohistochemical organic insoluble substrates ... New Fuchsin, and any other organic ... sections. Clarin can be used for ...
... industry's first siRNA sequence design software in ... these tools consistent with new experimental strategies ... of RNAi. With the introduction of ... tools, OligoEngine is pleased to offer the ...
... been designed and created in order to ... genotyping analysis tool. We incorporated the suggestions ... the software. Their main requirements were ease- ... acquisition cost. GeneMarker can perform analysis ...
Biology Products: